Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Crit Rev Ther Drug Carrier Syst ; 34(4): 283-316, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29199587

RESUMEN

Rheumatoid arthritis (RA) is a very painful severe autoimmune disease with complex pathology characterized by progressive chronic inflammation, and devastation of the synovium, cartilage, and other joint-associated structures. Significant advances in research in the area of pathophysiology, diagnosis, drug development, and targeted delivery have led to improved RA therapy and better patient compliance. Targeted drug delivery using liposomal nanomedicines significantly alleviate the challenges with conventional anti-RA medications such as off-target effects, short biological half-life, poor bioavailability, high dose-related toxicity, etc. Liposomal nanomedicines in RA drug targeting offer the opportunity for passive targeting [based on size and polyethylene glycol (PEG)-ylation-mediated enhanced permeability and retention] and active targeting (ligation with antibody or peptides, etc.) and encapsulation of lipophilic, hydrophilic drugs, and/or combinational drugs. However, it has been found recently that such injectable nanomedicines raise the concern of an adverse immune phenomenon called complement activationrelated pseudo allergy (CARPA) and failure of therapy on multiple doses due to accelerated body clearance caused many by anti-PEG immunoglobulin M. To ensure safety and efficacy of RA therapy, these need to be considered along with the common formulation quality parameters. Here, we discuss nanotherapeutic targeting in RA therapy using liposomes. Liposomal nanoparticles are investigated for individual anti-RA drug categories. CARPA issues and pathophysiology with such nanomedicines are also discussed in detail.


Asunto(s)
Antirreumáticos/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Liposomas/administración & dosificación , Nanopartículas/administración & dosificación , Animales , Antirreumáticos/química , Antirreumáticos/farmacocinética , Artritis Reumatoide/metabolismo , Humanos , Liposomas/química , Liposomas/farmacocinética , Nanomedicina/métodos , Nanopartículas/química , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química
2.
Int J Pharm Compd ; 18(4): 348-50, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25474865

RESUMEN

Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of ketoprofen in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date for this formulation. A stability-indicating high-performance liquid chromatography method for ketoprofen in Pluronic lecithin organogel was validated in our laboratory. Samples of the formulation were analyzed by high-performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined as the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Ketoprofen in Pluronic lecithin organogel was chemically and physically stable for six months when stored at room temperature and protected from light. Therefore, a beyond-use date of six months is appropriate for this preparation.


Asunto(s)
Antiinflamatorios no Esteroideos/química , Estabilidad de Medicamentos , Cetoprofeno/química , Cromatografía Líquida de Alta Presión/métodos , Geles , Lecitinas/química , Poloxámero/química , Factores de Tiempo
3.
J Drug Target ; 22(1): 34-47, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23987115

RESUMEN

PURPOSE: Oral immunization for mucosal protection against Mycobacterium tuberculosis would be the best option for effective tuberculosis (TB) control. However, this route of vaccine delivery is limited due to the short residence time of the delivery system at the site of absorption. Cytoadhension has made it possible to optimize the targeted delivery of oral vaccine to lymphoid tissues. The purpose of this project was to evaluate the ability of human M-cell specific lectin-labeled microparticles to target the human M-cells of the Peyer's patches. METHOD: Albumin microspheres containing Mycobacterium tuberculosis cell lysate antigens were coupled with Wheat germ agglutinin and Aleuria aurantia lectins and their ability to bind to M cell models as well as their preferential distribution in the Peyer's patches were investigated. RESULTS: The study demonstrated an enhanced delivery of targeted polystyrene and BSA/Lysate microspheres to M cells. It was demonstrated that alpha-l-fucose sugar residue might be the target of these lectins. CONCLUSION: It can be concluded from the study that the lectin-coupled microspheres had better affinity for M-cells and showed preferential binding to the Peyer's patches. This means that the coupling enhanced the targeted delivery of the antigens to the M cells.


Asunto(s)
Antígenos Bacterianos/administración & dosificación , Antígenos Bacterianos/química , Vacuna BCG/administración & dosificación , Vacuna BCG/química , Lectinas/administración & dosificación , Lectinas/química , Administración Oral , Albúminas/inmunología , Fosfatasa Alcalina/metabolismo , Animales , Antígenos Bacterianos/inmunología , Vacuna BCG/inmunología , Células CACO-2 , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos/métodos , Fucosa/administración & dosificación , Fucosa/química , Fucosa/inmunología , Humanos , Lectinas/inmunología , Ratones , Microesferas , Mycobacterium tuberculosis/inmunología , Mycobacterium tuberculosis/metabolismo , Ganglios Linfáticos Agregados/inmunología , Poliestirenos/administración & dosificación , Poliestirenos/química , Poliestirenos/inmunología , Tuberculosis/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA